Medical and Economic Evaluation of a Magnetic Anal Sphincter for Patients With Severe Anal Incontinence

NCT ID: NCT01920607

Last Updated: 2017-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

NA

Total Enrollment

71 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-30

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare 2 surgical treatments of severe fecal incontinence (defined as more than a major leak per week). The hypothesis of this "non-inferiority" trial is that magnetic anal sphincter is clinically as effective as SNS, but more cost-effective in managing fecal incontinence

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Severe anal incontinence, defined as the uncontrolled passing of stool at least once a week, is a problem that has a serious impact on the quality of life. In the event of failure of conservative treatments, surgery can help improve continence problems in a significant number of cases.

Sacral nerve stimulation is currently the standard surgical treatment for severe anal incontinence when sphincter repair (sphincteroplasty) is not recommended.

A new method of treatment based on sphincter reinforcement through the implanting of a band of magnetic beads\*, has proved to be reliable and efficient on a small series of cases, particularly after the failure of sacral nerve stimulation.

The aim of our trial, which compares the "magnetic anal sphincter\* and sacral nerve stimulation" in a homogeneous population of patients affected by severe anal incontinence is to define the position of this new approach in the treatment algorithm of this functional disorder, determining its clinical and medical/economic advantages compared to those of the current standard treatment.

\* FenixTM (Torax Medical)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fecal Incontinence Anal Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NMS

Implantation under general of local anesthesia of sacral nerve stimulation system (Interstim Therapy)

Group Type ACTIVE_COMPARATOR

sacral nerve stimulation

Intervention Type DEVICE

SAM

Implantation under general anesthesia of magnetic anal sphincter (Fenix)

Group Type EXPERIMENTAL

magnetic anal sphincter

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

magnetic anal sphincter

Intervention Type DEVICE

sacral nerve stimulation

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fenix Interstim

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (male or female) of 18 to 75 years of age
* Affected by severe anal incontinence (SAI)\*.
* Documented failure of conservative treatment (reeducation and medical treatment)
* With functional anal sphincter\*\*
* Agrees to take part in the study and has signed the informed consent form
* Agrees to undergo post-operative surveillance for a period of one (1) year
* Covered by National Insurance

* Defined as follows: at least one involuntary passing of stool per week measured by collecting data on incontinence accidents on a 3-week stool record chart, with the continence problem developing over more than 6 months. \*\*Defined as follows: external sphincter intact (without injury or after sphincter repair) or external sphincter altered, with an injury of a size that does not justify sphincter repair.

Internal sphincter injuries not taken into account (by professional consensus).

Exclusion Criteria

* Anorectal or pelvic malformations
* Local conditions incompatible with the proposed sizes of the MAS (extreme obesity, thickness of the tissue in the anorectal area)
* Sequelae of rectal resections - presence of cancer of the rectum or anus
* Rectal prolapse and/or major pelvic floor disorders
* Major chronic disorder of the intestinal motility, irritable bowel syndrome, repeated faecalomas, megarectum
* Extensive sphincter degeneration
* Consequences of radiation-induced rectitis and chronic inflammatory diseases of the bowel (Crohn's disease)
* Neurological disorders or systemic diseases (multiple sclerosis, scleroderma, paraplegia)
* Festering sores of the perineal and/or anorectal regions
* Known or suspected risks of allergy to titanium
* Active pelvic infection
* Contraindications to SNS:

* Cardiac stimulator or defibrillator implant
* Malformation of the sacrum
* Patient exposed to Magnetic Resonance Imaging
* Skin diseases exposing the patient to the risk of infection (at the investigator's discretion)
* Patient scheduled for diathermy or ablation by radiofrequency
* Pregnant women
* Adults under guardianship
* Patients involved in a mobility project in the year following the operation
* Patient already subjected to one or other of the therapeutic approaches (MAS or SNS) Please note: coagulation problems (including anti-aggregant or anti-coagulant treatments) are not a contraindication if these problems can be corrected during the perioperative period.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nantes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nantes University Hospital

Nantes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Wong MT, Meurette G, Wyart V, Lehur PA. Does the magnetic anal sphincter device compare favourably with sacral nerve stimulation in the management of faecal incontinence? Colorectal Dis. 2012 Jun;14(6):e323-9. doi: 10.1111/j.1463-1318.2012.02995.x.

Reference Type BACKGROUND
PMID: 22339789 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC13_0209

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.